{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:12:18Z","timestamp":1793905938596,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union through the Horizon\/EDCTP Global Health call for vulnerable adults","award":["Project 101103140"],"award-info":[{"award-number":["Project 101103140"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Men who are mobile for work are a key population at high risk of acquiring HIV. Flexible pre-exposure prophylaxis (PrEP) options, including event-driven (ED) oral PrEP and long-acting injectable cabotegravir (CAB-LA), may offer increased access and acceptability for these men. However, limited data exist on the effectiveness and implementation of CAB-LA and ED PrEP among mobile men in Africa. Our study aims to assess the effectiveness and implementation of CAB-LA and oral tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC) (both daily and ED) through comparison of uptake, retention in care, coital coverage, and participant choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We will conduct a mixed0method, phase 3b, open-label, hybrid type 2 implementation and effectiveness randomised controlled trial (RCT). The trial will be carried out in 400 HIV-negative men aged 18\u00a0years or older in South Africa and Uganda. Men will be randomised 1:1 to either Group A: oral TDF\/FTC PrEP (ED or daily) or Group B: CAB-LA over 9 months. After 9\u00a0months, participants from both groups will be offered a choice of PrEP (oral TDF\/FTC or CAB-LA) for a further 9\u00a0months, with the ability to change their choice as required. Various strategies to support PrEP adoption, initiation, and persistence will be implemented, monitored, and reported on using a RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) implementation science framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will provide critical data to inform scalable delivery models for both oral and injectable PrEP among mobile men at high risk for HIV acquisition. Findings will also highlight the potential of PrEP choice delivery and its benefits, offering evidence for governments to consider in the rollout of injectable PrEP in public health systems.<\/jats:p>\n                    <jats:p>Trial registration<\/jats:p>\n                    <jats:p>NCT06133686. Registered on 14 November 2023. PACTR202409632006463. Registered on 2 September 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09138-5","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:18:23Z","timestamp":1762777103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Implementing oral (event-driven and daily) and long-acting pre-exposure prophylaxis in mobile men in sub-Saharan Africa: a phase 3b, open-label, hybrid type 2 implementation and effectiveness trial (MOBILE MEN)"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-109X","authenticated-orcid":false,"given":"Sylvia","family":"Kusemererwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Nayiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limakatso","family":"Lebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loveleen Bansi-","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshini","family":"Govindasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Meyer-Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geofrey","family":"Kimbugwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Ruzagira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"12","key":"9138_CR1","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O\u2019reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973\u201383.","journal-title":"AIDS"},{"key":"9138_CR2","unstructured":"What\u2019s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to WHO\u2019s recommendation on oral PrEP. 2019.\u00a0[cited on 19 Dec 2024].\u00a0Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/325955\/WHO-CDS-HIV-19.8-eng.pdf?sequence=1.\u00a0"},{"key":"9138_CR3","unstructured":"UNAIDS. The AIDS response in the 2030 agenda for sustainable development: joint work, shared gains | UNAIDS UNAIDS.org2024. Available from: https:\/\/www.unaids.org\/en\/site-search#?cludoquery=the%20aids%20response%20in%20the%202030%20agenda%20for%20sustainable%20development%3A%20joint%20work%20shared%20gains&cludopage=1&cludorefurl=https%3A%2F%2Fwww.unaids.org%2Fen%2FAIDS_SDGs&cludorefpt=The%20AIDS%20response%20in%20the%202030%20agenda%20for%20sustainable%20development%3A%20joint%20work%2C%20shared%20gains%20%7C%20UNAIDS&cludoinputtype=standard. Cited 6 Dec 2024."},{"key":"9138_CR4","unstructured":"World Health Organization. Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance: technical brief. 2022.\u00a0[cited on 19 Dec 2024]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240053694."},{"key":"9138_CR5","unstructured":"Technical Guidance on Pre-Exposure Prophylaxis (PrEP) for Persons at Substantial Risk of HIV Infection in Uganda. 2022.\u00a0[cited on 19 Dec 2024].\u00a0Available from: http:\/\/library.health.go.ug\/communicable-disease\/hivaids\/technical-guidance-pre-exposure-prophylaxis-prep-persons-substantial."},{"issue":"8","key":"9138_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25975","volume":"25","author":"JJ Dietrich","year":"2022","unstructured":"Dietrich JJ, Ahmed N, Webb EL, Tshabalala G, Hornschuh S, Mulaudzi M, et al. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe. J Int AIDS Soc. 2022;25(8):e25975.","journal-title":"J Int AIDS Soc"},{"issue":"10337","key":"9138_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"key":"9138_CR8","volume-title":"Guidelines on long-acting injectable cabotegravir for HIV prevention","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: World Health Organization; 2022."},{"key":"9138_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10461-020-03023-9","volume":"25","author":"MM Philbin","year":"2021","unstructured":"Philbin MM, Parish C, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, et al. Interest in long-acting injectable pre-exposure prophylaxis (LAI PrEP) among women in the Women\u2019s interagency HIV study (WIHS): a qualitative study across six cities in the United States. AIDS Behav. 2021;25:667\u201378.","journal-title":"AIDS Behav"},{"issue":"3","key":"9138_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/COH.0000000000000734","volume":"17","author":"O Sued","year":"2022","unstructured":"Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS. 2022;17(3):145\u201361.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"9138_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/apc.2022.0068","volume":"36","author":"AR Bazzi","year":"2022","unstructured":"Bazzi AR, Valasek CJ, Streuli SA, Vera CF, Harvey-Vera A, Philbin MM, et al. Long-acting injectable human immunodeficiency virus pre-exposure prophylaxis preferred over other modalities among people who inject drugs: findings from a qualitative study in California. AIDS Patient Care STDS. 2022;36(7):254\u201362.","journal-title":"AIDS Patient Care STDS"},{"issue":"12","key":"9138_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2352-4642(20)30248-0","volume":"4","author":"K Gill","year":"2020","unstructured":"Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health. 2020;4(12):875\u201383.","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"9138_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"7","key":"9138_CR14","first-page":"e25963","volume":"25","author":"HMA Schmidt","year":"2022","unstructured":"Schmidt HMA, Rodolph M, Schaefer R, Baggaley R, Doherty M. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice. African Journal of Reproduction and Gynaecological Endoscopy. 2022;25(7):e25963.","journal-title":"African Journal of Reproduction and Gynaecological Endoscopy"},{"issue":"6","key":"9138_CR15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/hiv.13451","volume":"24","author":"G Liegeon","year":"2023","unstructured":"Liegeon G, Ghosn J. Long-acting injectable cabotegravir for PrEP: a game-changer in HIV prevention? HIV Med. 2023;24(6):653\u201363.","journal-title":"HIV Med"},{"key":"9138_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26115","volume":"26","author":"NM Mgodi","year":"2023","unstructured":"Mgodi NM, Murewanhema G, Moyo E, Samba C, Musuka G, Dzinamarira T, et al. Advancing the use of long-acting extended delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations. J Int AIDS Soc. 2023;26:e26115.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"9138_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.molmed.2022.11.003","volume":"29","author":"C Pike","year":"2023","unstructured":"Pike C, Bekker L-G. Interrogating the promise of long-acting HIV pre-exposure prophylaxis. Trends Mol Med. 2023;29(2):93\u20138.","journal-title":"Trends Mol Med"},{"issue":"4","key":"9138_CR18","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"Lancet HIV"},{"key":"9138_CR19","unstructured":"UNAIDS. Male engagement in HIV testing, treatment and prevention in Eastern and Southern Africa. 2021.\u00a0[cited on 9 Apr 2024]. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/east-south-africa-engaging-men_en.pdf."},{"issue":"3","key":"9138_CR20","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/S2352-3018(17)30205-9","volume":"5","author":"CC Iwuji","year":"2018","unstructured":"Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018;5(3):e116\u201325.","journal-title":"Lancet HIV"},{"issue":"5","key":"9138_CR21","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(20)30315-5","volume":"8","author":"K Gigu\u00e8re","year":"2021","unstructured":"Gigu\u00e8re K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, et al. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000\u201320: a modelling study using survey and HIV testing programme data. Lancet HIV. 2021;8(5):e284\u201393.","journal-title":"Lancet HIV"},{"issue":"5","key":"9138_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062637","volume":"8","author":"S Mhlongo","year":"2013","unstructured":"Mhlongo S, Dietrich J, Otwombe KN, Robertson G, Coates TJ, Gray G. Factors associated with not testing for HIV and consistent condom use among men in Soweto, South Africa. PLoS ONE. 2013;8(5):e62637.","journal-title":"PLoS ONE"},{"issue":"1","key":"9138_CR23","doi-asserted-by":"publisher","DOI":"10.3402\/gha.v8.25670","volume":"8","author":"K Otwombe","year":"2015","unstructured":"Otwombe K, Dietrich J, Laher F, Hornschuh S, Nkala B, Chimoyi L, et al. Health-seeking behaviours by gender among adolescents in Soweto, South Africa. Glob Health Action. 2015;8(1):25670.","journal-title":"Glob Health Action"},{"issue":"8","key":"9138_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085058","volume":"14","author":"C Mutie","year":"2024","unstructured":"Mutie C, Otieno B, Mwangi E, Kithuci K, Mutisya A, Gachohi J, et al. Global burden of HIV among long-distance truck drivers: a systematic review and meta-analysis. BMJ Open. 2024;14(8):e085058.","journal-title":"BMJ Open"},{"issue":"9","key":"9138_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/tmi.13922","volume":"28","author":"N Mlangeni","year":"2023","unstructured":"Mlangeni N, Adetokunboh O, Lembani M, Malotle M, Ngah V, Nyasulu PS. Provision of HIV prevention and care services to farmworkers in sub-Saharan African countries. Trop Med Int Health. 2023;28(9):710\u20139.","journal-title":"Trop Med Int Health"},{"issue":"6","key":"9138_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0956462413512803","volume":"25","author":"S Delany-Moretlwe","year":"2014","unstructured":"Delany-Moretlwe S, Bello B, Kinross P, Oliff M, Chersich M, Kleinschmidt I, et al. HIV prevalence and risk in long-distance truck drivers in South Africa: a national cross-sectional survey. Int J STD AIDS. 2014;25(6):428\u201338.","journal-title":"Int J STD AIDS"},{"key":"9138_CR27","unstructured":"Uganda AIDS Commission. The HIV and AIDS Uganda country progress report 2014. 2015.\u00a0[cited on 9 Apr 2024].\u00a0Available from: https:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/UGA_narrative_report_2015.pdf."},{"issue":"4","key":"9138_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249465","volume":"16","author":"PM Musumari","year":"2021","unstructured":"Musumari PM, Techasrivichien T, Srithanaviboonchai K, Wanyenze RK, Matovu JK, Poudyal H, et al. HIV epidemic in fishing communities in Uganda: a scoping review. PLoS ONE. 2021;16(4):e0249465.","journal-title":"PLoS ONE"},{"issue":"4","key":"9138_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/cid\/ciw321","volume":"63","author":"RL Glaubius","year":"2016","unstructured":"Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Rev Infect Dis. 2016;63(4):539\u201347.","journal-title":"Rev Infect Dis"},{"issue":"1","key":"9138_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0272989X17729376","volume":"38","author":"M Quaife","year":"2018","unstructured":"Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38(1):120\u201333.","journal-title":"Med Decis Making"},{"issue":"7","key":"9138_CR31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/infdis\/jiaa296","volume":"224","author":"JA Smith","year":"2021","unstructured":"Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224(7):1179\u201386.","journal-title":"J Infect Dis"},{"key":"9138_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25427","author":"MM van Vliet","year":"2019","unstructured":"van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019. https:\/\/doi.org\/10.1002\/jia2.25427.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"9138_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/QAI.0000000000002327","volume":"84","author":"M Vogelzang","year":"2020","unstructured":"Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. JAIDS J Acquir Immune Defic Syndr. 2020;84(2):173\u201381.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"10","key":"9138_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/infdis\/jiv523","volume":"213","author":"RP Walensky","year":"2016","unstructured":"Walensky RP, Jacobsen MM, Bekker L-G, Parker RA, Wood R, Resch SC, et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213(10):1523\u201331.","journal-title":"J Infect Dis"},{"issue":"12","key":"9138_CR35","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2352-3018(22)00251-X","volume":"9","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022;9(12):e857\u201367.","journal-title":"Lancet HIV"},{"issue":"4","key":"9138_CR36","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","volume":"10","author":"J Smith","year":"2023","unstructured":"Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, et al. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023;10(4):e254\u201365.","journal-title":"Lancet HIV"},{"key":"9138_CR37","doi-asserted-by":"crossref","unstructured":"Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis.\u00a0Ann\u00a0Intern\u00a0Med. 2022;175(4):479\u201389.","DOI":"10.7326\/M21-1548"},{"issue":"5","key":"9138_CR38","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1016\/S2352-3018(22)00029-7","volume":"9","author":"AN Phillips","year":"2022","unstructured":"Phillips AN, Bershteyn A, Revill P, Bansi-Matharu L, Kripke K, Boily M-C, et al. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022;9(5):e353\u201362.","journal-title":"Lancet HIV"},{"issue":"5","key":"9138_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/1049732318809940","volume":"29","author":"V Bond","year":"2019","unstructured":"Bond V, Ngwenya F, Murray E, Ngwenya N, Viljoen L, Gumede D, et al. Value and limitations of broad brush surveys used in community-randomized trials in Southern Africa. Qual Health Res. 2019;29(5):700\u201318.","journal-title":"Qual Health Res"},{"key":"9138_CR40","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.2147\/PPA.S427021","volume":"17","author":"E Rugira","year":"2023","unstructured":"Rugira E, Biracyaza E, Umubyeyi A. Uptake and persistence on HIV pre-exposure prophylaxis among female sex workers and men having sex with men in Kigali, Rwanda: a retrospective cross-sectional study design. Patient Prefer Adherence. 2023;17:2353\u201364.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"9138_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2025.2513684","volume":"26","author":"S Kansiime","year":"2025","unstructured":"Kansiime S, Holm Hansen C, Bern H, Fox J, Dunn D, Ruzagira E, et al. Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm. HIV Res Clin Pract. 2025;26(1):2513684.","journal-title":"HIV Res Clin Pract"},{"key":"9138_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-09085-7","volume":"20","author":"Z Kwena","year":"2020","unstructured":"Kwena Z, Nakamanya S, Nanyonjo G, Okello E, Fast P, Ssetaala A, et al. Understanding mobility and sexual risk behaviour among women in fishing communities of Lake Victoria in East Africa: a qualitative study. BMC Public Health. 2020;20:1\u201310.","journal-title":"BMC Public Health"},{"key":"9138_CR43","unstructured":"Global Data Lab. Subnational Human Development Index - South Africa. Available from: https:\/\/globaldatalab.org\/shdi\/table\/shdi\/ZAF\/. Cited 1 Jul 2023."},{"issue":"1","key":"9138_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sdata.2019.38","volume":"6","author":"J Smits","year":"2019","unstructured":"Smits J, Permanyer I. The subnational human development database. Sci Data. 2019;6(1):1\u201315.","journal-title":"Sci Data"},{"issue":"1","key":"9138_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v18i1.694","volume":"18","author":"LF Johnson","year":"2017","unstructured":"Johnson LF, Dorrington RE, Moolla H. Progress towards the 2020 targets for HIV diagnosis and antiretroviral treatment in South Africa. South Afr J HIV Med. 2017;18(1):1\u20138.","journal-title":"South Afr J HIV Med"},{"key":"9138_CR46","unstructured":"Thembisa version 4.6: National and Provincial Model Outputs. Thembisa. 2023. 2023. Available from: https:\/\/thembisa.org\/content\/downloadPage\/ProvOutput4_6. Cited 4 July 2023"},{"key":"9138_CR47","unstructured":"Johnson L, Dorrington R. Thembisa version 4.6: National and Provincial Model Outputs. Thembisa. 2023.\u00a0[cited 4 July 2023]. Available from: https:\/\/thembisa.org\/content\/downloadPage\/ProvOutput4_6."},{"issue":"3","key":"9138_CR48","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/QAI.0b013e31824445f0","volume":"59","author":"MD Nglazi","year":"2012","unstructured":"Nglazi MD, van Schaik N, Kranzer K, Lawn SD, Wood R, Bekker L-G. An incentivized HIV counseling and testing program targeting hard-to-reach unemployed men in Cape Town, South Africa. JAIDS J Acquir Immune Defic Syndr. 2012;59(3):e28.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"10","key":"9138_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/hiv.12787","volume":"20","author":"K Baisley","year":"2019","unstructured":"Baisley K, Seeley J, Siedner M, Koole K, Matthews P, Tanser F, et al. Findings from home-based HIV testing and facilitated linkage after scale-up of test and treat in rural South Africa: young people still missing. HIV Med. 2019;20(10):704\u20138.","journal-title":"HIV Med"},{"issue":"1","key":"9138_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ije\/dyaa264","volume":"50","author":"D Gareta","year":"2021","unstructured":"Gareta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort profile update: Africa centre demographic information system (ACDIS) and population-based HIV survey. Int J Epidemiol. 2021;50(1):33\u20134.","journal-title":"Int J Epidemiol"},{"key":"9138_CR51","doi-asserted-by":"crossref","unstructured":"Gareta D, Baisley K, Mngomezulu T, Smit T, Khoza T, Nxumalo S, et al. Cohort profile update: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey.\u00a0Int J\u00a0Epidemiol. 2021;50(1):33-4.","DOI":"10.1093\/ije\/dyaa264"},{"key":"9138_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/17290376.2010.9724963","author":"P Reddy","year":"2010","unstructured":"Reddy P, Buchanan D, Sifunda S, James S, Naidoo N. The role of community advisory boards in health research: divergent views in the South African experience. SAHARA-J J Soc Aspects HIV AIDS. 2010. https:\/\/doi.org\/10.1080\/17290376.2010.9724963.","journal-title":"SAHARA-J J Soc Aspects HIV AIDS"},{"issue":"5","key":"9138_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1017\/cts.2019.389","volume":"3","author":"MK Stewart","year":"2019","unstructured":"Stewart MK, Boateng B, Joosten Y, Burshell D, Broughton H, Calhoun K, et al. Community advisory boards: experiences and common practices of clinical and translational science award programs. J Clin Transl Sci. 2019;3(5):218\u201326.","journal-title":"J Clin Transl Sci"},{"issue":"2","key":"9138_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1086\/430707","volume":"41","author":"DA Diallo","year":"2005","unstructured":"Diallo DA, Doumbo OK, Plowe CV, Wellems TE, Emanuel EJ, Hurst SA. Community permission for medical research in developing countries. Clin Infect Dis. 2005;41(2):255\u20139.","journal-title":"Clin Infect Dis"},{"issue":"sup3","key":"9138_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/09540121.2016.1178958","volume":"28","author":"V Bond","year":"2016","unstructured":"Bond V, Chiti B, Hoddinott G, Reynolds L, Schaap A, Simuyaba M, et al. \u201cThe difference that makes a difference\u201d: highlighting the role of variable contexts within an HIV Prevention Community Randomised Trial (HPTN 071\/PopART) in 21 study communities in Zambia and South Africa. AIDS Care. 2016;28(sup3):99\u2013107.","journal-title":"AIDS Care"},{"key":"9138_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:1\u20138.","journal-title":"BMC Med Res Methodol"},{"key":"9138_CR57","doi-asserted-by":"crossref","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC medical research methodology. 2013;13:1-8.","DOI":"10.1186\/1471-2288-13-117"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09138-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:03:38Z","timestamp":1762819418000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09138-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9138"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09138-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5704553\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol, informed consent forms, and other relevant documents were approved by the Uganda Virus Research Institute Research Ethics Committee (Reference number: GC\/127\/1002), Uganda National Council for Science and Technology (Reference number: HS4366ES), London School of Hygiene and Tropical Medicine Research Ethics Committee (Reference number: 31223) and National Drug Authority (Reference number: CTC 0276\/2024) in Uganda, and the University of Cape Town Human Research Ethics Committee (Reference number: 803\/2023), the University of KwaZulu-Natal Biomedical Research Ethics Committee (Reference number: BREC\/000006454\/2023) and South Africa Health Products Regulatory Authority (Reference number: 20231108) in South Africa. The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents. This study will be conducted only in compliance with the most recent approved protocol and the ICH-GCP guidelines. Informed consent will be obtained prior to conducting any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"486"}}